Ether Solvent Crystallization for Citalopram Intermediate Resolution

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing S-5-cyano diol, a key intermediate for the anti-depression drug citalopram, face challenges such as small crystal particle sizes, low chiral purity, and complex operation processes, which hinder efficient large-scale industrial production.

Innovation Solution

The method involves crystallizing the salt of (S)-4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxymethyl benzonitrile with D-(+)di-p-toluoyl tartaric acid in ether solvents or mixed solvents containing water, which results in larger, easier-to-filter crystals with high chiral purity and simplified processing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If racemic 5-cyano diol is resolved by DPTT in isopropanol or 1-propanol, then the (S)-5-cyano diol resolved intermediate can be obtained, but the crystal particle size is small and difficult to filter

Engineering Contradiction:
Improvechiral purityVSAvoidfiltration difficulty
Core Design Contradiction:
Manufacturing precisionVSEase of operation

Solution Approach 1:

The patent changes the solvent parameter from aliphatic alcohols (isopropanol, 1-propanol) to aromatic alcohols (methanol, ethanol, propanol, butanol, pentanol, or their mixtures). This parameter change fundamentally alters the crystallization behavior, producing larger crystal particles that are easy to filter while maintaining high chiral purity above 99.0%.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent employs composite solvent systems comprising multiple aromatic alcohols in various ratios. By combining different aromatic alcohols (e.g., ethanol and propanol, or propanol and butanol), the method optimizes both crystal growth characteristics and chiral purity, achieving large, filterable crystals with superior enantiomeric excess.

Inventive Principle:
Principle #40Composite materials

2Productivity

If racemic 5-cyano diol is resolved by DPTT in isopropanol, then the resolved intermediate can be obtained, but the chiral purity is low and requires repurification

Engineering Contradiction:
Improveproduction efficiencyVSAvoidchiral purity
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent changes the solvent parameter from aliphatic alcohols to aromatic alcohols, which fundamentally improves the chiral resolution capability. This single parameter change achieves chiral purity above 99.0% in one crystallization step, eliminating the need for repurification and significantly improving production efficiency.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The aromatic alcohol solvent system performs multiple functions simultaneously: it serves as the crystallization medium, provides the chiral discrimination environment needed for high-purity resolution, and facilitates easy crystal separation. This multi-functional solvent system eliminates the need for separate repurification steps.

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Manufacturing precision

If racemic 5-cyano diol is resolved by DPTT in 1-propanol, then the resolved intermediate can be obtained, but the yield is small and requires two times of refinements

Engineering Contradiction:
Improvechiral purityVSAvoidyield
Core Design Contradiction:
Manufacturing precisionVSProductivity

Solution Approach 1:

The patent changes the solvent parameter from 1-propanol (aliphatic) to aromatic alcohols (methanol, ethanol, propanol, butanol, pentanol, or their mixtures). This parameter change simultaneously improves chiral purity to above 99.0% and increases yield, while eliminating the need for multiple refinement steps.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses composite aromatic alcohol systems that optimize both yield and chiral purity. By selecting appropriate combinations of aromatic alcohols and their ratios, the method achieves high yield with single-step crystallization, avoiding the need for two refinement cycles required by conventional methods.

Inventive Principle:
Principle #40Composite materials

4Manufacturing precision

If small crystal particles are obtained from the resolution process, then the resolution can be completed, but the operation becomes very complex

Engineering Contradiction:
Improveresolution completenessVSAvoidoperation complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent changes the solvent parameter to aromatic alcohols, which naturally promote the formation of large, well-formed crystal particles during crystallization. This parameter change simplifies the entire operation sequence - crystals are easily filtered, washed, and dried in a single step, eliminating complex multi-step processing procedures.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach achieves high yield and chiral purity (>99.0%) with reduced need for post-processing refinement, efficient solvent recovery, and lower production costs, while ensuring good crystallinity and easy separation of crystal particles.

Implementation Method 1

a salt of (S)-4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxymethyl benzonitrile of formula IV with a resolving agent D-(+)di-p-toluoyl tartaric acid of formula II was crystallized in a resolving solvent

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Data Source

PatentEP3219702B1Method for resolution of citalopram intermediate 5-cyanogen diol
Publication Date: 2021.05.05 ZHEJIANG HUAHAI PHARMACEUTICAL CO LTD
  • EP3219702B1 patent drawingFigure 1~2
  • EP3219702B1 patent drawingFigure 3~4
  • EP3219702B1 patent drawingFigure 5

AI summary

Provided is a method for resolution of formula 4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxy-methyl benzonitrile as an enantiomer thereof, comprising the following steps: a salt of (S)-4-[4-dimethylamino-1-(4-fluorophenyl)-1-hydroxylbutyl]-3-hydroxymethyl benzonitrile with a resolving agent D-(+)di-p-toluoyl tartaric acid was crystallized in a resolving solvent; the method is characterized in that the resolving solvent is an ether solvent. Also provided is a new crystal form of the resolved intermediate.